Absent Influenza Vaccine Response in Rituximab-treated Lymphoma Patients

    loading  Checking for direct PDF access through Ovid

Abstract

SYNOPSIS: Lymphoma patients treated with rituximab, either in combination with chemotherapy or as a single agent, were found to have markedly deficient influenza vaccine response, with none of 67 achieving a protective titer, compared with 42 of 51 controls. Thus, rituximab-treated lymphoma patients are particularly susceptible to vaccine failure and influenza infection should be highly considered in symptomatic patients, even in those who had been appropriately vaccinated.

Related Topics

    loading  Loading Related Articles